WASHINGTON, March 7, 2021 /PRNewswire-PRWeb/ -- The Front
Line COVID-19 Critical Care Alliance (FLCCC), a group of highly
published, world-renowned critical care physicians and scholars, is
troubled by the recently updated consumer guidance on Ivermectin
from the FDA. The guidance from the FDA is misleading and has the
potential to raise unwarranted concern over an important drug in
the prevention and treatment of COVID-19.
We support the FDA's direction that humans should never take
medication formulations meant for animals. We also agree that
self-dosing of medications without the guidance of a physician is
potentially dangerous and could cause serious harm.
However, the FLCCC feels that other statements recently made by
the FDA are misleading and serve to alarm the public about using
Ivermectin as a treatment prescribed by a physician.
The FDA consumer guidance statement admits that they have not
reviewed data on the use of Ivermectin to treat or to prevent
COVID-19. However, the agency felt compelled to use language to
discourage any discourse and interest in using Ivermectin as a
front-line treatment of COVID-19. To do this is to ignore the
growing body of scientific evidence from peer-reviewed research,
over 40 medical trials, and results from Ivermectin's use in
medical settings worldwide, showing the safe and effective use of
the drug in fighting COVID-19. [Source available here]
According to the American Medical Association Journal of Ethics,
10-20% of all prescriptions in the U.S. are prescribed 'off-label."
[Source available here] Ivermectin is often one of many drugs
prescribed by a physician for a number of conditions it is known to
be effective for, but might not have gone through FDA approval. It
is therefore misleading to suggest that because a drug has not
received FDA approval for COVID it should not be used. FDA approval
would only come many months to years from now after a very large
Phase III trial is done and our patients cannot wait for that.
"Due to its extensive record of safe use, medical professionals
can feel confident about prescribing Ivermectin," said Dr.
Pierre Kory, president and chief
medical officer of the FLCCC. "In the 40 years since it was first
approved for use, more than 3.8 billion people have been treated
with an average of only 160 adverse events reported per year.
[Source available here] This is a better safety record than several
vitamins."
During this time of a pandemic, the FDA should be working as
fast as it can to approve the use of Ivermectin in the prevention
and treatment of COVID-19 instead of issuing misleading guidance
that could prevent people from taking a life-saving drug. In the
meantime, the public deserves to have clear and science-based
information on safe and effective treatments for COVID-19.
About the Front Line COVID-19 Critical Care Alliance
The FLCCC Alliance was organized in March
2020 by a group of highly published, world renowned Critical
Care physician/scholars – with the academic support of allied
physicians from around the world – to research and develop
lifesaving protocols for the prevention and treatment of COVID-19
in all stages of illness. Their MATH+ Hospital Treatment Protocol,
introduced in March 2020, has saved
thousands of patients who were critically ill with COVID-19. Now,
the FLCCC's new I-Mask+ Prophylaxis and Early At-Home Outpatient
Treatment Protocol with Ivermectin has been released – and is a
potential solution to the global pandemic.
For more information: http://www.FLCCC.net
Media Contact
Joyce Kamen, jkamen@flccc.net, +1
513-486-4696, jkamen@flccc.net
SOURCE jkamen@flccc.net